Vir Biotechnology Files Q1 2025 10-Q Report
Ticker: VIR · Form: 10-Q · Filed: 2025-05-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biotechnology
TL;DR
**VIR Q1 2025 10-Q FILED. CHECK FINANCIALS.**
AI Summary
Vir Biotechnology, Inc. filed its Q1 2025 10-Q report on May 8, 2025, for the period ending March 31, 2025. The company, based in San Francisco, CA, operates in the biological products sector. Key financial data and operational details for the first quarter of 2025 are presented in this filing.
Why It Matters
This filing provides investors and analysts with the latest financial performance and operational updates for Vir Biotechnology, Inc. during the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or significant new disclosures.
Key Numbers
- Q1 2025 — Reporting Period (The first quarter of fiscal year 2025.)
- 2025-03-31 — End of Reporting Period (The specific date the financial information in the report pertains to.)
- 2024-12-31 — Previous Fiscal Year End (Provides a comparison point for financial trends.)
Key Players & Entities
- Vir Biotechnology, Inc. (company) — Filer of the 10-Q report
- 0001706431 (company) — Central Index Key for Vir Biotechnology, Inc.
- 20250331 (date) — Conformed period of report
- 20250508 (date) — Filing date
- SAN FRANCISCO, CA (location) — Company headquarters location
FAQ
What were Vir Biotechnology's collaboration and contract revenues for Q1 2025 compared to Q1 2024?
The filing indicates Vir Biotechnology, Inc. had collaboration revenue of $XXX for the period 2025-01-01 to 2025-03-31 and $XXX for the period 2024-01-01 to 2024-03-31. Contract revenue was $XXX for 2025-01-01 to 2025-03-31 and $XXX for 2024-01-01 to 2024-03-31. (Note: Specific dollar amounts are not present in the provided text, placeholders are used).
What is the company's fiscal year end?
Vir Biotechnology, Inc.'s fiscal year ends on December 31st.
What is the company's primary business sector?
The company is classified under STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on May 8, 2025.
What is the company's SEC file number?
The SEC file number for Vir Biotechnology, Inc. is 001-39083.
From the Filing
0001628280-25-023291.txt : 20250508 0001628280-25-023291.hdr.sgml : 20250508 20250507173328 ACCESSION NUMBER: 0001628280-25-023291 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 25923030 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 10-Q 1 vir-20250331.htm 10-Q vir-20250331 12/31 false 0001706431 Q1 2025 http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2024#AccruedLiabilitiesAndOtherLiabilities http://fasb.org/us-gaap/2024#AccruedLiabilitiesAndOtherLiabilities 364 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure vir:segment vir:engager vir:diseaseTarget 0001706431 2025-01-01 2025-03-31 0001706431 2025-04-30 0001706431 2025-03-31 0001706431 2024-12-31 0001706431 vir:CollaborationRevenueMember 2025-01-01 2025-03-31 0001706431 vir:CollaborationRevenueMember 2024-01-01 2024-03-31 0001706431 vir:ContractRevenueMember 2025-01-01 2025-03-31 0001706431 vir:ContractRevenueMember 2024-01-01 2024-03-31 0001706431 us-gaap:GrantMember 2025-01-01 2025-03-31 0001706431 us-gaap:GrantMember 2024-01-01 2024-03-31 0001706431 2024-01-01 2024-03-31 0001706431 us-gaap:CommonStockMember 2024-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001706431 us-gaap:RetainedEarningsMember 2024-12-31 0001706431 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001706431 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001706431 us-gaap:CommonStockMember 2025-03-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001706431 us-gaap:RetainedEarningsMember 2025-03-31 0001706431 us-gaap:CommonStockMember 2023-12-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001706431 us-gaap:RetainedEarningsMember 2023-12-31 0001706431 2023-12-31 0001706431 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001706431 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001706431 us-gaap:CommonStockMember 2024-03-31 0001706431 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001706431 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001706431 us-gaap:RetainedEarningsMember 2024-03-31 0001706431 2024-03-31 0001706431 srt:MaximumMember 2023-11-01 2023-11-30 0001706431 us-gaap:CommonStockMember vir:SalesAgreementMember 2023-11-01 2023-11-30 0001706431 us-gaap:CommonStockMember vir:SalesAgreementMember 2025-01-01 2025-03-31 0001706431 vir:SanofiAgreementMember 2024-09-09 0001706431 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2025-03-31 0001706431 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2025-03-31 0001706431 us-gaap:FairValueInputsLevel2Member vir:USGovernmentAgencyBondsAndDiscountNotesMember 2025-03-31 0001706431 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMe